Gland Pharma Overview

  • Year Founded
  • 1978

Year Founded

  • Status
  • Public

  • Employees
  • 2,880

Employees

  • Stock Symbol
  • GLAND

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $22.89
  • (As of Thursday Closing)

Gland Pharma General Information

Description

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Contact Information

Formerly Known As
Gland Chemicals
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NSE
Corporate Office
  • Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Road
  • D.P. Pally, Dundigal Gandimaisamma Mandal, Medchal-Malkajgiri District
  • Hyderabad, Andhra Pradesh 500043
  • India
+91 040 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gland Pharma Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$22.89 $23.57 $10.39 - $26.41 $3.77B 165M 328K $0.48

Gland Pharma Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Mar-2023 FY 2022 31-Mar-2022 FY 2021 31-Mar-2021
EV 3,574,377 2,128,317 6,686,830 5,319,110
Revenue 590,931 447,317 588,416 460,167
EBITDA 129,924 128,047 213,885 181,526
Net Income 79,774 97,268 162,623 134,001
Total Assets 1,069,114 1,033,074 884,473
Total Debt 0 542 625 680
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Gland Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Gland Pharma‘s full profile, request access.

Request a free trial

Gland Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key m
Pharmaceuticals
Hyderabad, India
2,880 As of 2023
00000
000000&0

00000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. D
000000000000000
Mumbai, India
00000 As of 0000
0000 0000-00-00
0&0

000000

ercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute ir
000000000000000
Pune, India
0000 As of 0000
00.000
00000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Gland Pharma Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cipla Corporation Mumbai, India 00000 0&0
Emcure Private Equity-Backed Pune, India 0000 00.000 00000000 00.000
Natco Pharma Corporation Hyderabad, India 0000 000.00 0000 000.00
Glenmark Corporation Mumbai, India 00000 00000 000000000 00000
MSN Laboratories Corporation Hyderabad, India 00000 00.000 000000000000 00.000
You’re viewing 5 of 8 competitors. Get the full list »

Gland Pharma Patents

Gland Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190295732-A1 Apparatus for predicting outbreak of avian influenza Inactive 21-Mar-2018 000000000
JP-2020521153-A Apparatus and methods associated with seismic shock mitigation Pending 23-May-2017 0
US-20180079669-A1 Method for selection of appropriate location to reduce the atmospheric carbon dioxide through large-scale iron fertilization with less accumulation rate of volcanic sulfur compounds Inactive 23-Jul-2015 C02F3/322 0

Gland Pharma Executive Team (6)

Name Title Board Seat Contact Info
Srinivas Sadu Chief Executive Officer & Managing Director
Ravi Mitra Chief Financial Officer
Prakash Baliga Chief Operating Officer
Ravi Penmetsa Co-Founder & Managing Director
K.V.G.K. Raju Chief Technical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

Gland Pharma Board Members (7)

Name Representing Role Since
00000 000000 Self Independent Director 000 0000
0.0.0. 0000 Gland Pharma Co-Founder & Chairman 000 0000
0000 0000 Self Non-Executive Director 000 0000
00000000 0000 Gland Pharma Chief Executive Officer & Managing Director 000 0000
0000000 0000 Fosun Pharma Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Gland Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gland Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Gland Pharma‘s full profile, request access.

Request a free trial

Gland Pharma Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cenexi 27-Apr-2023 0000000000 00000 Pharmaceuticals 00000000
Vitane Biologics (Equipment and Facility) 19-May-2021 Corporate Asset Purchase 000.00 Buildings and Property 00000000
To view Gland Pharma’s complete investments and acquisitions history, request access »

Gland Pharma Subsidiaries (1)

Company Name Industry Location Founded
Cenexi Pharmaceuticals Fontenay-Sous-Bois, France 0000
To view Gland Pharma’s complete subsidiaries history, request access »

Gland Pharma ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

44.83 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

0.000

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,605

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 870

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 418

Rank

00.00

Percentile

To view Gland Pharma’s complete esg history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »